Business

Inhaled drug developer MannKind Corporation has announced that it "is committed to joining the global effort to overcome the COVID-19 crisis" and as a result "that it is adjusting research and development resources that were reserved for its pipeline of investigational products for treating serious lung diseases, with the goal of prioritizing work on new compounds … [Read more...] about MannKind to focus R&D on potential COVID-19 therapies, collaboration with Immix

According to the FDA, three DPIs marketed by Sunovion in the US have been discontinued as of March 10, 2020. Sunovion acquired the US rights to Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler from Novartis in December 2016. The inhalers are marketed elsewhere as Ultibro Breezhaler, Seebri Breezhaler, … [Read more...] about FDA lists Arcapta, Seebri, and Utibron Neohalers as discontinued (updated)

Mylan Pharmaceuticals has announced the launch of the Wixela Inhub fluticasone propionate/salmeterol DPI in Canada. According to the company, Health Canada approved Wixela Inhub, a generic version of Advair Diskus, in January 2020 for asthma and COPD. The inhaler will be available in 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg strengths for asthma and 250 … [Read more...] about Mylan launches Wixela Inhub in Canada

Neurelis has announced the launch of Valtoco diazepam nasal spray for the treatment of seizure clusters in the US. The FDA approved Valtoco for the treatment of acute repetitive seizures in epilepsy patients aged 6 and older in January 2020. According to the company, patients can now obtain Valtoco through Maxor Specialty Pharmacy, which has already started filling … [Read more...] about Neurelis launches Valtoco nasal spray in the US

Hikma Pharmaceuticals has signed an agreement with Glenmark Pharmaceuticals for exclusive US rights to Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis, the companies said. According to the announcement, the deal includes an upfront payment, milestone payments, and royalties; the amounts were not … [Read more...] about Hikma to distribute Ryaltris nasal spray in the US

Aradigm Corporation, which filed for bankruptcy in February 2019, said that it will sell all of its assets related to Lipoquin inhaled ciprofloxacin, Apulmiq (Linhaliq) dual release inhaled ciprofloxacin, and other inhaled ciprofloxacin candidates to Grifols, subject to approval by the bankruptcy court. The deal also leaves Aradigm "free to accept higher and better … [Read more...] about Grifols agrees to acquire all assets related to Aradigm’s inhaled ciprofloxacin programs

Apollo Global Management has agreed to acquire Covis Pharma, which markets several ciclesonide aerosol products: the Alvesco MDI and Omnaris and Zetonna nasal sprays. Terms of the deal were not disclosed. Covis is currently owned by Cerberus Capital Management, which founded the company in 2011. In 2017, Covis acquired the US rights to the three ciclesonide … [Read more...] about Apollo Global Management agrees to acquire Covis Pharma